The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels
- 1 January 2004
- journal article
- research article
- Published by Springer Science and Business Media LLC in Angiogenesis
- Vol. 7 (3), 225-233
- https://doi.org/10.1007/s10456-004-3149-y
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- The biology of VEGF and its receptorsNature Medicine, 2003
- Role of angiogenesis in tumor growth and metastasisSeminars in Oncology, 2002
- Tumor angiogenesis and accessibility: Role of vascular endothelial growth factorSeminars in Oncology, 2002
- VEGF and the quest for tumour angiogenesis factorsNature Reviews Cancer, 2002
- Clinical translation of angiogenesis inhibitorsNature Reviews Cancer, 2002
- Angiogenesis: How a Tumor Adapts to HypoxiaBiochemical and Biophysical Research Communications, 1999
- Vessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGFScience, 1999
- Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in MiceScience, 1999
- Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinomaCell, 1994
- The fms -Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth FactorScience, 1992